VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
MNPR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
MNPRMonopar Therapeutics Inc.
$71.97$482M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
MNPR logo

Monopar Therapeutics Inc.

MNPR
NASDAQ · Rare Disease Biotech
$71.97
At close - Nov 16, 4:00 PM EST - USD
Market Cap$482M
P/E-29.9x
52W High$124.82
Volume200.03K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Cash-Funded Clinical Burn Pressures Monopar's Runway Outlook

Monopar Therapeutics reports zero revenue across all ten quarters, with R&D driving the expense base and quarterly operating losses ranging from -$1.6M to -$11.1M, including -$7.5M in 2026Q3.

GrowthMixed
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

MNPR price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

7/12 Beats

EPS beat 7 of last 12 quarters

02

Valuation risk

-192% Peers

P/E is 192% below peer median

03

Market leadership

RS 50 · Avg

Average momentum (RS Rating: 50)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 12

Market performance

Price History →

Trailing total returns as of 11/17/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
MNPR+9.03%
S&P 500 (^GSPC)+8.31%
1-Year Return
MNPR-5.84%
S&P 500 (^GSPC)+11.16%
3-Year Return
MNPR+4209.58%
S&P 500 (^GSPC)+32.76%
5-Year Return
MNPR+196.78%
S&P 500 (^GSPC)+57.97%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
-
Net income FY25
-$14M+12.0% YoY
Free cash flow FY25
-$12M-90.5% YoY
Operating margin FY25
-
ROIC (FY25)-29.4%
Avg ROIC 5Y-2225.3%
ROE (TTM)-15.5%
Piotroski Score5 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate7/12 (58%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 12, 2026
-$0.72-0.6%
vs -$0.72
—
vs —
Q3 2026
Aug 12, 2026
-$0.62+3.6%
vs -$0.64
—
vs —
Q2 2026
May 14, 2026
-$0.46+56.6%
vs -$1.06
—
vs —
Q2 2026
Mar 27, 2026
-$0.61-19.1%
vs -$0.51
—
vs —
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
GlobeNewsWire·5d ago
Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates

WILMETTE, Ill., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced third quarter 2026 financial results and provided business updates.

GlobeNewsWire·Nov 9, 2026
Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026

WILMETTE, Ill., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the presentation of baseline data from the Phase 3 FoCus trial characterizing residual disease burden in treatment-experienced patients with Wilson disease, along with molybdenum balance and long-term uric acid data for ALXN1840 (tiomolibdate choline, TMC), the Company's investigational therapy for Wilson disease, at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2026, held Nov. 5–9, 2026, in Denver, Colorado.

GlobeNewsWire·Nov 2, 2026
Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data

WILMETTE, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that two abstracts related to ALXN1840 (tiomolibdate choline, TMC), the Company's investigational therapy for Wilson disease, will be presented at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2026, taking place Nov. 5–9, 2026, at the Colorado Convention Center in Denver, Colorado.

Defense World·Aug 24, 2026
Monopar Therapeutics (NASDAQ:MNPR) and Regenicin (OTCMKTS:RGIN) Head-To-Head Contrast

Regenicin (OTCMKTS:RGIN - Get Free Report) and Monopar Therapeutics (NASDAQ: MNPR - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership. Profitability This table compares Regenicin and Monopar Therapeutics' net

Filtered for Monopar Therapeutics Inc.More Headlines
04

Compare before deciding

Benchmark MNPR against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Monopar Therapeutics Inc. (MNPR)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
MNPR logoMNPRMonopar Therapeutics Inc.Current
$71.97$482.13M-29.91——-15.52%—
CLDX logoCLDXCelldex Therapeutics, Inc.
$28.59$1.9B-7.26-78.63%-275986.61%-52.67%—
IMVT logoIMVTImmunovant, Inc.
$33.28$6.87B-13.51—-7173.52%-63.01%—
TPVG logoTPVGTriplePoint Venture Growth BDC Corp.
$3.78$153.46M7.0655.25%58.87%6.24%27.11%
NKTR logoNKTRNektar Therapeutics
$36.44$1.25B-7.03-43.89%-339.67%-29.31%—
ADXN logoADXNAddex Therapeutics Ltd
$3.83$2.76M-0.68-92.58%-14429.21%-172.46%—

Compare MNPR vs Peers

Monopar Therapeutics Inc. (MNPR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs CLDX

Most directly comparable listed peer for MNPR.

Scale Benchmark

vs IQV

Larger-name benchmark to compare MNPR against a more recognizable public peer.

Peer Set

Compare Top 5

vs CLDX, IMVT, TPVG, NKTR

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

MNPR SEC Filings & Documents

Monopar Therapeutics Inc. (MNPR) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 12, 2026·SEC

Material company update

Aug 12, 2026·SEC

Material company update

Jul 22, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 27, 2026·SEC

FY 2025

Mar 31, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 12, 2026·SEC

FY 2026

Aug 12, 2026·SEC

FY 2026

May 14, 2026·SEC

Get notified when MNPR posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

MNPR Frequently Asked Questions

Monopar Therapeutics Inc. (MNPR) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
Is MNPR profitable?

No. Monopar Therapeutics Inc. (MNPR) reported a net loss of $20.6M over the trailing twelve months.

Dividend & Returns
What is MNPR's return on equity?

Monopar Therapeutics Inc. (MNPR) had a return on equity (ROE) of -15.5% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Monopar Therapeutics Inc.'s free cash flow?

Monopar Therapeutics Inc. (MNPR) had negative free cash flow of $3.26B over the trailing twelve months.

What if you invested $1,000 in MNPR back in 2015?

Total return calculator · dividends reinvested · 11+ years of data

See returns →